Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GMED NYSE:HAE NYSE:HRC NASDAQ:IRTC NYSE:NVRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMEDGlobus Medical$56.83-1.7%$60.18$54.48▼$94.93$7.69B1.191.15 million shs290,864 shsHAEHaemonetics$75.91-2.9%$70.50$55.30▼$94.99$3.65B0.39672,955 shs225,541 shsHRCHill-Rom$155.96$155.74$93.34▼$156.22$10.30B0.55656,912 shsN/AIRTCiRhythm Technologies$134.75+0.0%$142.96$55.92▼$157.13$4.28B1.41486,463 shs89,616 shsNVRONevro$5.85+0.1%$5.85$3.17▼$10.37$224.32M0.81802,121 shs753,602 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMEDGlobus Medical+0.86%-2.27%-5.91%-20.61%-16.83%HAEHaemonetics+0.72%+1.96%+8.56%+30.66%-10.00%HRCHill-Rom0.00%0.00%0.00%0.00%0.00%IRTCiRhythm Technologies+1.38%-5.38%-9.30%+31.95%+42.10%NVRONevro0.00%0.00%0.00%0.00%-27.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMEDGlobus Medical4.9406 of 5 stars4.35.00.04.12.02.51.9HAEHaemonetics4.9075 of 5 stars4.52.00.04.32.81.72.5HRCHill-RomN/AN/AN/AN/AN/AN/AN/AN/AIRTCiRhythm Technologies1.2579 of 5 stars2.51.00.00.02.70.80.6NVRONevro0.1933 of 5 stars1.00.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMEDGlobus Medical 2.62Moderate Buy$94.0065.40% UpsideHAEHaemonetics 3.00Buy$97.3028.19% UpsideHRCHill-Rom 0.00N/AN/AN/AIRTCiRhythm Technologies 2.90Moderate Buy$138.602.86% UpsideNVRONevro 1.92Reduce$5.36-8.29% DownsideCurrent Analyst Ratings BreakdownLatest HRC, GMED, HAE, IRTC, and NVRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025HAEHaemoneticsBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$95.007/9/2025HAEHaemoneticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$90.006/26/2025HAEHaemoneticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$87.006/25/2025HAEHaemoneticsBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/11/2025IRTCiRhythm TechnologiesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$130.00 ➝ $160.006/10/2025GMEDGlobus MedicalBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/27/2025GMEDGlobus MedicalJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/27/2025GMEDGlobus MedicalBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral5/22/2025IRTCiRhythm TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $167.005/20/2025HAEHaemoneticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$100.00 ➝ $100.005/12/2025GMEDGlobus MedicalTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$80.00 ➝ $68.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMEDGlobus Medical$2.52B3.05$6.60 per share8.61$30.40 per share1.87HAEHaemonetics$1.36B2.68$7.05 per share10.76$16.34 per share4.65HRCHill-Rom$3.02B3.41$9.29 per share16.79$28.56 per share5.46IRTCiRhythm Technologies$591.84M7.27N/AN/A$2.90 per share46.46NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMEDGlobus Medical$102.98M$1.3442.4114.101.677.39%10.52%8.56%8/5/2025 (Estimated)HAEHaemonetics$167.68M$3.3122.9215.061.2612.32%26.37%9.22%8/14/2025 (Estimated)HRCHill-Rom$248.50M$3.7241.9221.72N/A8.23%23.07%8.96%N/AIRTCiRhythm Technologies-$113.29M-$3.14N/AN/AN/A-15.90%-101.04%-9.55%7/30/2025 (Estimated)NVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)Latest HRC, GMED, HAE, IRTC, and NVRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025IRTCiRhythm Technologies-$0.53N/AN/AN/AN/AN/A8/5/2025Q2 2025GMEDGlobus Medical$0.79N/AN/AN/A$738.91 millionN/A5/8/2025Q1 2025GMEDGlobus Medical$0.74$0.68-$0.06$0.54$629.74 million$598.12 million5/8/2025Q4 2025HAEHaemonetics$1.22$1.24+$0.02$1.17$329.38 million$330.60 million5/1/2025Q1 2025IRTCiRhythm Technologies-$0.89-$0.95-$0.06-$0.97$153.39 million$158.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMEDGlobus MedicalN/AN/AN/AN/AN/AHAEHaemoneticsN/AN/AN/AN/AN/AHRCHill-Rom$0.960.62%N/A25.81%N/AIRTCiRhythm TechnologiesN/AN/AN/AN/AN/ANVRONevroN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMEDGlobus MedicalN/A4.452.72HAEHaemonetics1.121.620.99HRCHill-Rom0.971.381.05IRTCiRhythm Technologies7.475.715.58NVRONevro0.675.023.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMEDGlobus Medical95.16%HAEHaemonetics99.67%HRCHill-Rom76.45%IRTCiRhythm TechnologiesN/ANVRONevro95.52%Insider OwnershipCompanyInsider OwnershipGMEDGlobus Medical18.51%HAEHaemonetics1.84%HRCHill-Rom0.69%IRTCiRhythm Technologies1.10%NVRONevro3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMEDGlobus Medical5,300135.38 million110.32 millionOptionableHAEHaemonetics3,02348.04 million47.16 millionOptionableHRCHill-Rom10,00066.05 million65.59 millionOptionableIRTCiRhythm Technologies2,00031.92 million31.57 millionOptionableNVRONevro1,09038.37 million36.27 millionOptionableHRC, GMED, HAE, IRTC, and NVRO HeadlinesRecent News About These CompaniesNevro Corp. (NYSE:NVRO) Receives Average Rating of "Reduce" from AnalystsJuly 6, 2025 | americanbankingnews.comZimmer hires former Nevro CEO Kevin ThornalMay 27, 2025 | medtechdive.comMNevro Corp. Data Breach - Levi & Korsinsky, LLP Launches InvestigationApril 22, 2025 | accessnewswire.comANevro Corp. Data Breach under Investigation by Levi & Korsinsky, LLPApril 21, 2025 | accessnewswire.comAINVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data BreachApril 21, 2025 | accessnewswire.comANevro Corp. Data Breach - Levi & Korsinsky, LLP Launches InvestigationApril 18, 2025 | accessnewswire.comANevro Corp. Data Breach - Levi & Korsinsky, LLP Launches InvestigationApril 17, 2025 | accessnewswire.comANevro Corp. Data Breach Under Investigation by Levi & Korsinsky, LLPApril 16, 2025 | accessnewswire.comAINVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data BreachApril 15, 2025 | accessnewswire.comALevi & Korsinsky, LLP Investigates Nevro Corp. Data BreachApril 14, 2025 | accessnewswire.comALevi & Korsinsky, LLP Investigates Nevro Corp. Data BreachApril 14, 2025 | accessnewswire.comAINVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data BreachApril 11, 2025 | accessnewswire.comADATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Nevro Corp. Customers Whose Data May Have Been CompromisedApril 10, 2025 | globenewswire.comINVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data BreachApril 10, 2025 | accessnewswire.comANevro Corp. Data Breach - Levi & Korsinsky, LLP Launches InvestigationApril 9, 2025 | accessnewswire.comAINVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data BreachApril 8, 2025 | accessnewswire.comANevro Files Notice of Data Breach Affecting Confidential Consumer InformationApril 5, 2025 | jdsupra.comNevro Corp. Investigated by Federman & Sherwood for Data BreachApril 3, 2025 | globenewswire.comWhy Is Nevro (NVRO) Up 0.9% Since Last Earnings Report?April 3, 2025 | zacks.comGlobus Medical Completes Acquisition of Nevro Corp.April 3, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRC, GMED, HAE, IRTC, and NVRO Company DescriptionsGlobus Medical NYSE:GMED$56.83 -0.97 (-1.67%) As of 12:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.Haemonetics NYSE:HAE$75.90 -2.27 (-2.90%) As of 12:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.Hill-Rom NYSE:HRCHill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.iRhythm Technologies NASDAQ:IRTC$134.74 +0.04 (+0.03%) As of 12:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.Nevro NYSE:NVRO$5.85 +0.01 (+0.10%) Closing price 04/2/2025Extended Trading$5.85 0.00 (0.00%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
